CV Therapeutics In regulatory update

CVTX received U.S. Patent No. 5,866,702 covering purine inhibitors of cyclin dependent kinase 2 (CDK2), a cell cycle regulator. The inhibitors could prevent cellular proliferation that occurs followi...